Evidence map›Paper›PMID 35620443›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2022

Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of

Funda Ceran, Sema Akıncı, Mehmet Ali Uçar, Gülten Korkmaz, Mehmet Gündüz, Büşranur Çavdarlı, Şule Mine Bakanay, Mesude Falay, Simten Dağdaş, İmdat Dilek and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Initial Rate ofTurkish journal of haematology : official journal of Turkish Society of Haematology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Funda CeranAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyORCID 0000-0003-3173-7614
Sema AkıncıAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyORCID 0000-0003-4237-3342
Mehmet Ali UçarÇukurova University Faculty of Medicine, Department of Hematology, Ankara, TurkeyORCID 0000-0002-6041-7364
Gülten KorkmazAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyORCID 0000-0003-4467-9724
Mehmet GündüzBiruni University Faculty of Medicine, Department of Hematology, İstanbul, TurkeyORCID 0000-0001-9105-6429
Büşranur ÇavdarlıAnkara City Hospital, Clinic of Medical Genetics, Ankara, TurkeyORCID 0000-0002-0953-6210
Şule Mine BakanayAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyORCID 0000-0003-3941-0368
Mesude FalayDüzen Laboratory Group, Department of Biochemistry, Ankara, TurkeyORCID 0000-0001-7846-3476
Simten DağdaşAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyORCID 0000-0003-0901-2043
İmdat DilekAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyORCID 0000-0001-8316-4462
Gülsüm ÖzetAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyORCID 0000-0003-3173-7614

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of Materials and Methods: Forty patients with CP-CML who received first-line imatinib treatment were included in this study. Results: Of the 40 patients, Conclusion: Our findings revealed that MMR could be predicted via EMR as well as by HT and RR. Additionally, HT of ≤24 days and RR of ≤0.04 were more important than

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseChronic DiseaseFusion Proteins, bcr-ablHumansImatinib MesylateProtein Kinase InhibitorsRetrospective StudiesFusion Proteins, bcr-ablImatinib MesylateProtein Kinase InhibitorsBCR::ABL1 ISChronic myeloid leukemiaHalving timeMolecular responseReduction ratio

Identifiers

PMID35620443
PMCPMC9421336
OpenAlexW4281718633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.